- Email: [email protected]
JAAD game changers: Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])
Journal Pre-proof Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]) Adam Friedman PII:
S0190-9622(19)32485-5
DOI:
https://doi.org/10.1016/j.jaad.2019.07.092
Reference:
YMJD 13703
To appear in:
Journal of the American Academy of Dermatology
Received Date: 26 July 2019 Accepted Date: 26 July 2019
Please cite this article as: Friedman A, Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]), Journal of the American Academy of Dermatology (2019), doi: https://doi.org/10.1016/j.jaad.2019.07.092. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2019 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.
Title Page Author: (Corresponding Author) Adam Friedman George Washington School of Medicine and Health Sciences Department of Dermatology 2150 Pennsylvania Avenue, NW Bronx, NY 10467 202-741-2600 [email protected] Funding: None Conflicts: None Words: 267 Article Title: Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
Game Changer Information Game Changer Category: General Derm Game Changer Title: Game Changer: Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). Game Changer Author: Adam J. Friedman, MD Game Changer: • How to pick your poison is the challenge in today's world of almost too many biologics for psoriasis (a good problem to have). • Comparative data has been few and far between, and translation from FDA approval focused clinical trials to the real world is difficult. However this is fortunately changing as representative by this study utilizing real world data as the material for comparative analysis. • Based on this study, IL12/23 inhibition outperformed TNF-a inhibition for plaque psoriasis at both 6 and 12 months following initating therapy. Original authors: Bruce E. Strober, MD, PhD, Robert Bissonnette, MD, David Fiorentino, MD, PhD, Alexa B. Kimball, MPH, MD, Luigi Naldi, MD, Neil H. Shear, MD, Kavitha Goyal, MD, Steven Fakharzadeh, MD, PhD, Stephen Calabro, MS, Wayne Langholff, PhD, Yin You, MS, Claudia Galindo, MD, Seina Lee, MS, PharmD, and Mark G. Lebwohl, MD Original Article Title: Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). Original Capsule Summary: • Several biologics are effective for the treatment of psoriasis. • In a real-world setting, effectiveness was significantly better for ustekinumab than for tumor necrosis factor-α inhibitors for the majority of comparisons at 6 and 12 months.
•
These comparative effectiveness analyses of currently available biologic therapies will help inform treatment decisions in patients with psoriasis.
Link to the original article: https://www.jaad.org/article/S0190-9622(15)02568-2/fulltext
S0190-9622(19)32485-5
DOI:
https://doi.org/10.1016/j.jaad.2019.07.092
Reference:
YMJD 13703
To appear in:
Journal of the American Academy of Dermatology
Received Date: 26 July 2019 Accepted Date: 26 July 2019
Please cite this article as: Friedman A, Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]), Journal of the American Academy of Dermatology (2019), doi: https://doi.org/10.1016/j.jaad.2019.07.092. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2019 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.
Title Page Author: (Corresponding Author) Adam Friedman George Washington School of Medicine and Health Sciences Department of Dermatology 2150 Pennsylvania Avenue, NW Bronx, NY 10467 202-741-2600 [email protected] Funding: None Conflicts: None Words: 267 Article Title: Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
Game Changer Information Game Changer Category: General Derm Game Changer Title: Game Changer: Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). Game Changer Author: Adam J. Friedman, MD Game Changer: • How to pick your poison is the challenge in today's world of almost too many biologics for psoriasis (a good problem to have). • Comparative data has been few and far between, and translation from FDA approval focused clinical trials to the real world is difficult. However this is fortunately changing as representative by this study utilizing real world data as the material for comparative analysis. • Based on this study, IL12/23 inhibition outperformed TNF-a inhibition for plaque psoriasis at both 6 and 12 months following initating therapy. Original authors: Bruce E. Strober, MD, PhD, Robert Bissonnette, MD, David Fiorentino, MD, PhD, Alexa B. Kimball, MPH, MD, Luigi Naldi, MD, Neil H. Shear, MD, Kavitha Goyal, MD, Steven Fakharzadeh, MD, PhD, Stephen Calabro, MS, Wayne Langholff, PhD, Yin You, MS, Claudia Galindo, MD, Seina Lee, MS, PharmD, and Mark G. Lebwohl, MD Original Article Title: Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). Original Capsule Summary: • Several biologics are effective for the treatment of psoriasis. • In a real-world setting, effectiveness was significantly better for ustekinumab than for tumor necrosis factor-α inhibitors for the majority of comparisons at 6 and 12 months.
•
These comparative effectiveness analyses of currently available biologic therapies will help inform treatment decisions in patients with psoriasis.
Link to the original article: https://www.jaad.org/article/S0190-9622(15)02568-2/fulltext